Epitalon Compounding Pharmacy FDA and State Board Enforcement History

What is epitalon, and where does it stand federally?

Epitalon (also spelled epithalon) is a synthetic tetrapeptide, Ala-Glu-Asp-Gly, with a molecular weight of about 390 g/mol as the free base and about 450 g/mol as the acetate [1]. It was designed from the amino-acid content of epithalamin, a polypeptide extract of animal pineal gland, and FDA treats the two as different substances, so studies of epithalamin are not studies of epitalon [1]. FDA says epitalon first appears to have been synthesized in 1999 [1].

No FDA-approved epitalon product exists, and epitalon is not a component of an approved drug [1]. FDA's July 2026 review found no USP or National Formulary monograph, no listing in the European or Japanese pharmacopeias, and no approved product in Canada, Australia, the UK, Belgium, Ireland, France, Norway, Germany, Spain or Italy, or authorized by the European Medicines Agency [1]. It is sold online as research-use-only vials of 10 mg to 50 mg, as capsules and as oral sprays, promoted as an anti-aging peptide that lengthens telomeres [1].

What does federal law require before a pharmacy can compound with a bulk substance?

For a state-licensed pharmacy or physician to compound with a bulk drug substance, federal law requires one of three things: the substance complies with an applicable USP or National Formulary monograph, or it is a component of an FDA-approved drug product where no monograph exists, or it appears on FDA's list of bulk drug substances that can be used in compounding [8]. The substance must also be accompanied by a valid certificate of analysis and be made by an establishment registered with FDA [8].

Epitalon meets none of the three [1][8]. FDA's interim policy, under which the agency generally does not act against compounders of certain nominated substances, sorts substances into three categories. Epitalon appears in none of them, on either the list for state-licensed pharmacies and physicians or the list for outsourcing facilities [6][7][8].

What is the documented regulatory history?

• September 2, 2010: FDA granted epitalon an orphan drug designation for retinitis pigmentosa. The designation was withdrawn on January 6, 2016 [1].
• 2015: An analysis of illegal pharmaceutical preparations sold for cancer, old age and retinitis pigmentosa identified epitalon in two of them [9].
• October 25, 2018 to April 1, 2020: A Kentucky pharmacy compounded and distributed epitalon products, according to a US Attorney's office report cited by FDA [1].
• Content dated April 22, 2026: FDA's page on bulk substances that may present significant safety risks shows epitalon in the 'nominated but withdrawn' table, which holds substances that had been in category 2 and whose nominators withdrew them [2].
• July 2026: FDA staff proposed in a briefing document that neither epitalon free base nor epitalon acetate be added to the compounding list [1].
• July 24, 2026: The advisory committee voted in favor of adding epitalon to the bulks list, against FDA staff's recommendation [3][4].
• October 28, 2026: HHS filed a draft enforcement-discretion policy that names epitalon among six peptides (BPC-157, epitalon, KPV, MOTS-c, Semax, TB-500). Publication was scheduled for October 30, 2026, with comments due two weeks after publication [4][5].

FDA also found no pharmacy that compounds epitalon and no outsourcing facility that reports it [1].

Does the July 2026 vote or the HHS draft make epitalon legal to compound?

No. The advisory committee's recommendation is advice only and is not binding, epitalon is not on the list, and adding it takes formal rulemaking [3][4]. The HHS document is a draft: the notice says it 'does not establish any rights for any person and is not binding on HHS or the public', and HHS may revisit it if a safety signal or product quality issue arises [4].

The draft covers the acetate form given by subcutaneous or intramuscular injection in intermittent courses. It lists conditions such as a single active ingredient, a patient-specific prescription, an FDA-registered manufacturer supplying a certificate of analysis, and a label reading 'This is a compounded drug product. Not for resale.' [4][5]. Neither document is an FDA approval. Compounded drugs are not FDA-approved: FDA does not review their safety, effectiveness or quality before marketing [4][10].

What did FDA staff say about epitalon's safety?

FDA's July 2026 evaluation found only three human studies of epitalon: two sublingual studies in night-shift workers and one eye injection in retinitis pigmentosa. None were in insomnia, and none was a clinical study that assessed safety [1]. Staff evaluated only the nominated insomnia use and gave these reasons for recommending against listing: epitalon is not well characterized; historical use is limited; there is no evidence of effectiveness for insomnia; there are no clinical safety data; subcutaneous injection carries an immunogenicity concern; and many FDA-approved insomnia drugs exist [1]. The nominated products were 10 mg/mL and 3000 microgram/mL subcutaneous injections [1].

FDA's safety-risk page says the agency 'has not identified safety-related information regarding epitalon for the proposed route of administration', so it lacks enough information to know whether the drug would cause harm, and it notes that injectable peptides may pose immunogenicity risk from aggregation and impurities [2]. It adds that removal from category 2 was not a finding that epitalon is safe [2].

Are there reports of harm?

FDA searched its adverse-event database through December 8, 2025 and its food and supplement complaint system through December 5, 2025 and retrieved no epitalon reports [1]. A Russian-language abstract said 'no side effects' but did not report the dose, route or number of people [1]. FDA also found no pharmacokinetic data for epitalon [1].

What about state boards of pharmacy?

FDA says state boards of pharmacy generally have primary responsibility for day-to-day oversight of state-licensed pharmacies that are not registered with FDA as outsourcing facilities, and that FDA conducts surveillance and for-cause inspections of those pharmacies [10]. The one documented case involving epitalon products is the Kentucky pharmacy reported by a US Attorney's office [1].

Is there an approved dose or protocol?

There is no approved dose [1]. Websites FDA reviewed suggest 5 mg to 10 mg per day by subcutaneous injection or orally, in cycles, which is marketing rather than evidence [1]. The human studies FDA found used a sublingual spray delivering about 0.5 mg per day for 20 days, and a parabulbar injection beside the eye for retinitis pigmentosa [1].

What has not been shown

The telomerase finding comes from cultured human fetal fibroblasts that lack telomerase, where epitalon induced telomerase activity and telomere elongation [11]. That is a cell-culture result, not a human outcome. FDA found no study showing epitalon extends life or slows aging in people, and warned that because it activates telomerase and lengthens telomeres, and longer telomeres are generally linked to higher cancer risk, it has a mechanistic potential to be carcinogenic [1].

One mouse study is often cited. Female HER-2/neu transgenic mice injected with 1 microgram of epitalon per mouse for 5 consecutive days every month from 2 months of age had a lower cumulative number of mammary tumours and a smaller maximum tumour size than saline-treated mice, and HER-2/neu mRNA expression in their tumours was 3.7-fold lower [12]. This is a mouse result, not a human one. FDA rated the mouse cancer and chromosome-damage studies too limited, with one fixed dose, female mice only and short exposure, to show safety [1].

A 2026 narrative review by Jain and colleagues, searching through September 22, 2026, concluded that human evidence is limited to small physiological or biomarker studies and an older controlled study in retinitis pigmentosa, that no adequately powered randomized trial has established efficacy, that pharmacokinetic, dose-ranging and long-term safety data are inadequate, and that epitalon is 'biologically active but clinically unproven' [13].